Halozyme Therapeutics, Inc. (HALO) Financials
Key financial figures for Halozyme Therapeutics, Inc. (Q2 2026).
Halozyme Therapeutics, Inc. reported revenue of $481.0 million for Q2 FY2026, up 47.7% from the same period a year earlier. Net income was $229.9 million, or $1.90 per share. Operating margin came to 59.8%, against 62.15% a year earlier. Free cash flow for the period was $236.7 million. Across the last 5 reported quarters, quarterly revenue has risen from $325.7 million in Q2 FY2025 to $481.0 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Halozyme Therapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $481M
- Net Income
- $230M
- EPS
- $1.96
- Total Assets
- $2.6B
- Operating Cash Flow
- $241M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $481M | $230M | $1.90 | 59.8% | $237M |
| Q1 FY2026 | $377M | $150M | $1.22 | 48.98% | $176M |
| Q4 FY2025 | $452M | -$142M | -$1.20 | 53.28% | $218M |
| Q3 FY2025 | $354M | $175M | $1.43 | 61.51% | $176M |
| Q2 FY2025 | $326M | $165M | $1.33 | 62.15% | $98M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.4B | $317M | $2.56 | 57.47% | $645M |
| FY2024 | $1.0B | $444M | $3.43 | 54.32% | $468M |
| FY2023 | $829M | $282M | $2.10 | 40.71% | $373M |
Frequently asked questions
What was Halozyme Therapeutics, Inc.'s revenue last quarter?
Halozyme Therapeutics, Inc. reported revenue of $481.0 million for Q2 FY2026, up 47.7% from the same period a year earlier.
Is Halozyme Therapeutics, Inc. profitable?
Yes. Halozyme Therapeutics, Inc. reported net income of $229.9 million for Q2 FY2026, a net margin of 47.8% on revenue.
How has Halozyme Therapeutics, Inc.'s margin trended?
Operating margin was 59.8% in Q2 FY2026, compared with 62.15% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Halozyme Therapeutics, Inc. generate?
Halozyme Therapeutics, Inc. generated free cash flow of $236.7 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Halozyme Therapeutics, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.